Bio tech company updates — 9/24/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Korean biotech venture funding has reached 1.93 trillion won this year, surpassing all of 2025, while drugmakers ramp up AI-savvy hiring and Korea delivers its first approved advanced regenerative therapy. These developments mark strong momentum in capital, talent, and clinical innovation across the sector.
Key Findings
- Korean biotech venture investment reached 1.93 trillion won through September, already exceeding the total for all of 2025, with pre-IPO funding up 131%.
- Korean drugmakers including Hanmi, Samjin and Daewoong are expanding hiring of researchers skilled in both AI and pharmaceutical science.
- South Korea delivered its first approved advanced regenerative therapy to a patient at Yeouido St. Mary's Hospital, targeting rare blood cancer relapse.
Details
Record venture funding. Investment in Korean biotech ventures hit 1.93 trillion won through September, topping the full-year total for 2025. Pre-IPO funding surged 131%, signaling strong late-stage investor confidence in the pipeline of emerging companies.
AI-pharma talent war. Leading Korean drugmakers — Hanmi, Samjin and Daewoong — are aggressively recruiting researchers who combine AI expertise with pharmaceutical science, reflecting the industry's shift toward AI-driven drug discovery.
First approved regenerative therapy delivered. A patient at Yeouido St. Mary's Hospital received South Korea's first approved advanced regenerative therapy, aimed at treating relapse of a rare blood cancer.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
